Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore, Kathleen; Colombo, Nicoletta; Scambia, Giovanni; Kim, Byoung-Gie; Oaknin, Ana; Friedlander, Michael; Lisyanskaya, Alla; Floquet, Anne; Leary, Alexandra; S Sonke, Gabe; Gourley, Charlie; Banerjee, Susana; Oza, Amit; González-Martín, Antonio; Aghajanian, Carol; Bradley, William; Mathews, Cara; Liu, Joyce; S Lowe, Elizabeth; Bloomfield, Ralph; DiSilvestro, Paul

doi:10.1056/NEJMoa1810858

Public

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Shared by NobleBlocks on Dec 27, 2018 • 12:00 AM UTC

Authors:

Kathleen Moore

Nicoletta Colombo

Giovanni Scambia

Abstract

BACKGROUND: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib in relapsed disease has been well establis...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!